NCT02311569View on ClinicalTrials.gov

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Myeloproliferative NeoplasmPrimary MyelofibrosisEssential ThrombocythemiaPolycythemia Vera
Interventions
DRUG

Mirabegron

25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.

Trial Locations (11)

1011

Centre Hospitalier Universitaire Vaudois CHUV, Lausanne

1211

Hopitaux Universitaires de Geneve, Geneva

8063

Stadtspital Triemli, Zurich

8596

Kantonsspital Münsterlingen, Münsterlingen

CH-5001

Kantonsspital Aarau, Aarau

CH-4031

Universitaetsspital-Basel, Basel

CH-6500

Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni, Bellinzona

CH-3010

Inselspital Bern, Bern

CH-4410

Kantonsspital Liestal, Liestal

CH-6000

Kantonsspital Luzern, Lucerne

CH-8091

Universitätsspital Zürich, Zurich

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER

NCT02311569 - Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation | Biotech Hunter | Biotech Hunter